Drugs / KN5601
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07490041 | Mar → Dec 2026 expected | interstitial lung disease, systemic lupus erythematosus | The Children's Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT06926985 | Jul 2025 → Apr 2026 | IgA glomerulonephritis | Jieyang People's Hospital | Withdrawn | No outcome recorded |
| Phase 0 | NCT06792799 | Jan 2025 → Jun 2028 expected | IgA glomerulonephritis, idiopathic multidrug-resistant nephrotic syndrome, systemic lupus erythematosus | The Children's Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KN5601 | “A single arm, open-label pilot study is designed to evaluate the safety and effectiveness of anti-CD19/BCMA CAR NK cells (KN5601) in patients with IgA nephropathy” NCT06926985 ↗ |
| Known as | anti-CD19/BCMA CAR NK cells | “anti-CD19/BCMA CAR NK cells (KN5601)” NCT06792799 ↗ |
| Modality | Cell therapy | “anti-CD19/BCMA CAR NK cells (KN5601)” NCT06926985 ↗ |
| Target | CD19 | “anti-CD19/BCMA CAR NK cells (KN5601)” NCT06926985 ↗ |